| 產(chǎn)品名稱 |
HAA1 |
| 商品貨號(hào) |
B164547 |
| Organism |
human (B cell); human (myeloma) |
| Cell Type |
hybridoma: B lymphocyte |
| Product Format |
frozen |
| Morphology |
lymphoblast |
| Culture Properties |
suspension |
| Biosafety Level |
2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disclosure |
This material is cited in a US or other Patent and may not be used to
infringe the claims. Depending on the wishes of the Depositor, ATCC may be
required to inform the Patent Depositor of the party to which the material was
furnished. This material may not have been produced or characterized by ATCC. |
| Derivation |
Splenic B cells from a patient were fused with LTR228 lymphoblastoid cells. |
| Clinical Data |
Splenic B cells from a patient were fused with LTR228 lymphoblastoid cells. |
| Genes Expressed |
immunoglobulin; monoclonal antibody; against Blood group A antigen |
| Cellular Products |
immunoglobulin; monoclonal antibody; against Blood group A antigen |
| Comments |
Splenic B cells from a patient were fused with LTR228 lymphoblastoid cells. |
| Complete Growth Medium |
Iscove's modified Dulbecco's medium, 85%; fetal bovine serum, 15%
|
| Subculturing |
Medium Renewal: Every 2 to 3 days Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml. |
| Cryopreservation |
fetal bovine serum, 95%; DMSO, 5% |
| Name of Depositor |
Cetus Corp. |
| Deposited As |
human (B cell); human (myeloma) |
| U.S. Patent Number |
|
| References |
Raubitschek AR, et al. Human lymphoblastoid cell line and hybridomas derived therefrom. US Patent 4,624,921 dated Nov 25 1986
|
